Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT02947386 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

EGFR Gene Mutation
Recurrent Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nimotuzumab
BIOLOGICAL: Nivolumab

Sponsor

Roswell Park Cancer Institute